玻璃体腔注射康柏西普治疗BRVO继发不同类型黄斑水肿的疗效比较
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

山东省自然基金资助(No.ZR2019MH111)


Comparison of different types of macular edema secondary to BRVO treated by intravitreal injection of Conbercept
Author:
Affiliation:

Fund Project:

Natural Resources Fund of Shandong Province(No.ZR2019MH111)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察玻璃体腔注射康柏西普治疗视网膜分支静脉阻塞(BRVO)继发不同类型黄斑水肿(ME)的疗效。

    方法:选取BRVO继发ME的患者70例70眼。基于OCT形态学表现分为3组:囊样型水肿(CME,24眼)、弥漫型水肿(DRT,22眼)、伴有神经上皮层脱离型水肿(SRD,24眼)。所有患者行玻璃体腔注射0.5mg(0.05mL)康柏西普治疗,治疗后1、6mo,比较三组BCVA(LogMAR)、黄斑区中央视网膜厚度(CMT)、黄斑中心无血管区面积(FAZ)、视网膜浅层毛细血管区血流密度(SCP)和深层毛细血管区血流密度(DCP)、注射次数的差异。

    结果:随访6mo,CME组、DRT组、SRD组患眼BCVA值(0.24±0.13、0.11±0.07、0.33±0.13)、CMT(268.75±19.01、245.64±23.20、277.00±21.21μm)均呈明显下降趋势,FAZ(0.37±0.09、0.30±0.08、0.36±0.03mm2)呈明显变小趋势,SCP(46.18%±3.21%、47.49%±3.48%、42.76%±3.66%)、DCP(43.50%±4.34%、47.69%±2.76%、43.88%±3.54%)呈明显增加趋势(均P<0.01)。治疗6mo时,DRT组在提高BCVA、降低CMT,减小FAZ面积,增加SCP及DCP密度等方面均优于CME组和SRD组。随访6mo DRT组的注射次数(2.55±0.69次)最少(F=5.584,P<0.05)。

    结论:玻璃体腔注射康柏西普均可显著改善BRVO继发不同类型ME患眼的视力,降低CMT,减小FAZ面积,增加SCP及DCP密度,其中DRT疗效最佳,注射次数最少。

    Abstract:

    AIM: To observe the changes of microvascular structure of different patterns of macular edema(ME)secondary to branch retinal vein occlusion(BRVO)after intravitreal injection of conbercept.

    METHODS: A total of 70 patients(70 eyes)with ME secondary to BRVO were classified as cystoid macular edema(CME group, 24 eyes), diffuse retinal thickening(DRT group, 22 eyes)and serous retinal detachment(SRD group, 24 eyes)according to features under OCT examination. After an initial intravitreal injection of 0.5mg(0.05mL)conbercept(IVIC). The changes of best corrected visual acuity(BCVA), central macular thickness(CMT), foveal avascular zone(FAZ), vascular density of superficial capillary plexus(SCP), vascular density of deep retinal capillary plexus(DCP)and the injection times were compared among three groups after 1, 6mo treatment.

    RESULTS: After 6mo follow up, the BCVA(0.24±0.13、0.11±0.07、0.33±0.13)and the CMT(268.75±19.01、245.64±23.20、277.00±21.21μm)of the three groups showed a significant downward trend; The FAZ(0.37±0.09、0.30±0.08、0.36±0.03mm2)of the three groups showed a significant decreased trend; The SCP(46.18%±3.21%、47.49%±3.48%、42.76%±3.66%)and the DCP(43.50%±4.34%、47.69%±2.76%、43.88%±3.54%)of the three groups showed a significant increased trend(P<0.01). After 6mo treatment, DRT group was better than CME group and SRD group in improving BCVA, reducing CMT and FAZ area, increasing the density of SCP and DCP. The DRT group had the least injection numbers(2.55±0.69)(F=5.584, P<0.05).

    CONCLUSION: The intravitreal injection of conbercept significantly improved the BCVA, reduced the CMT and the FAZ, increased the vascular density of SCP and DCP of different patterns of ME. Best outcomes were achieved in DRT group.

    参考文献
    相似文献
    引证文献
引用本文

宋文琦,赵博军.玻璃体腔注射康柏西普治疗BRVO继发不同类型黄斑水肿的疗效比较.国际眼科杂志, 2020,20(7):1148-1152.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-02-10
  • 最后修改日期:2020-05-28
  • 录用日期:
  • 在线发布日期: 2020-06-22
  • 出版日期:
文章二维码